S

Sage Therapeutics

SAGE

9.76000
USD
-1.21
(-11.03%)
مفتوح الان
حجم التداول
3,089
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
465,204,185
أصول ذات صلة
A
ABCL
-0.19000
(-5.85%)
3.06000 USD
A
ARCT
-1.880
(-8.01%)
21.600 USD
C
CRSP
-2.450
(-4.28%)
54.840 USD
C
CRVS
0.36000
(13.85%)
2.96000 USD
E
EDIT
-0.28500
(-5.26%)
5.13500 USD
I
ILMN
-0.250
(-0.20%)
122.370 USD
S
SNDX
-0.750
(-3.30%)
21.990 USD
V
VYGR
-0.59000
(-6.37%)
8.67000 USD
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.